Diabetes Icon in white

Type 2 Diabetes

Explore facts and recommendations for pharmacological treatments for type 2 diabetes.

pharmacotherapies
Filters

We are still gathering material for this library.

Please check again soon.

We're sorry

We didn't find any resources that match your selection.

Please adjust your filter(s) and try again.

pharmacotherapies
 
Preview
type 2 diabetes PDF

Degludec Cardiovascular Outcomes Trial (DEVOTE) Overview

Summary and highlights from a clinical trial comparing the cardiovascular safety of degludec and glargine.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
type 2 diabetes PDF

SWITCH-1 and SWITCH-2 Trial Overview

Summary and highlights from a clinical trial comparing the effects of degludec and glargine on hypoglycemia.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
continuing education icon

Continuing Education

Find accredited opportunities in type 2 diabetes education.

Explore CE Activities

Type 2 Diabetes

disease education
View Resources
pharmacotherapies
 
Preview
type 2 diabetes PDF

Safety of GLP-1 RAs in Cardiovascular Outcome Trials (CVOTs)

Review of trials evaluating the safety of GLP-1 RAs in patients with type 2 diabetes and established cardiovascular disease and/or cardiovascular risk factors.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
type 2 diabetes PDF

Overview of Select Modern Non-Insulin Antidiabetic Drugs (NIADs)

Detailed breakdown of NIAD types, with quick-reference tables covering mechanism of action, efficacy, and more.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
type 2 diabetes PDF

Heart Failure and GLP-1 RAs

Detailed review of heart failure, its relationship to type 2 diabetes (T2D), and the effect of GLP-1 RAs on heart failure in T2D patients.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
Preview
type 2 diabetes PDF

Properties of Anti-Hyperglycemic Agents

Chart comparing efficacy and considerations for 7 types of agents.

Download
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close

Type 2 Diabetes

congress materials
View Resources
pharmacotherapies
 
type 2 diabetes Video

Ozempic® Mechanism of Action

This video discusses the mechanism of action and mechanism of protraction of Ozempic®

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® Mechanism of Action

This video discusses the mechanism of action of RYBELSUS®

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® Mechanism of Absorption

This video discusses the mechanism of absorption of RYBELSUS®.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

Pharmakinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for RYBELSUS®

This video describes PK/PD considerations that can impact the dosing of RYBELSUS®.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

Drug Interactions With RYBELSUS®

This video reviews potential drug-drug interactions with Rybelsus®

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® vs. Placebo in Drug-Naïve Adults (PIONEER 1 Study)

This video discusses the trial-design and outcomes of the PIONEER 1 study. PIONEER 1 was a 26-week, phase 3a, randomized, double-blind, parallel group, multinational trial in 703 adult patients with type 2 diabetes managed with diet and exercise alone.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)

This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® vs. Sitagliptin 100 mg (PIONEER 3 Study)

This video discusses the trial-design and outcomes of the PIONEER 3 study. PIONEER 3 was a 78-week, phase 3a, randomized, double-blind, double-dummy, multinational trial enrolling 1864 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® 14 mg vs. Victoza® 1.8 mg vs. Placebo (PIONEER 4 Study)

This video discusses the trial-design and outcomes of the PIONEER 4 study. PIONEER 4 was a 52-week, phase 3a, randomized, double-blind, double-dummy, active- and placebo-controlled, multinational trial in 711 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® 14 mg vs. Placebo in Adults with Moderate Renal Impairment (PIONEER 5 Study)

This video discusses the trial-design and outcomes of the PIONEER 5 study. PIONEER 5 was a 26-week, phase 3a, randomized, double-blind, multinational trial enrolling 324 adults with type 2 diabetes and moderate renal impairment.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

Cardiovascular Safety of RYBELSUS® vs. Placebo (PIONEER 6 Study)

This video discusses the trial-design and outcomes of the PIONEER 6 study. PIONEER 6 was a phase 3a, randomized, double-blind, multinational trial that enrolled 3183 adult patients (age ≥50 years) with type 2 diabetes. Eligible patients were at least 50 years of age with established cardiovascular (CV) disease or chronic kidney disease, or patients were at least 60 years of age with at least one CV risk factor.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

Flexible Dosing of RYBELSUS® vs. Sitagliptin 100 mg (PIONEER 7 Study)

This video discusses the trial-design and outcomes of the PIONEER 7 study. PIONEER 7 was a 52-week, phase 3a, randomized, open-label, multinational trial with a 52-week extension enrolling 504 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
pharmacotherapies
 
type 2 diabetes Video

RYBELSUS® vs. Placebo as Add-on to Insulin (PIONEER 8 Study)

This video discusses the trial-design and outcomes of the PIONEER 8 study. PIONEER 8 was a 52-week, phase 3a, randomized, double-blind, parallel-group, multinational trial enrolling 731 adults with type 2 diabetes.

Watch video
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close

Looking for additional resources?
Explore other libraries or search the Exchange.

Novo Nordisk® Scientific Exchange logo

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with permission for educational and informational purposes only and is not certified for continuing education credits.

Continue

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

Continue

GATED INTERSTITAL  

You are now leaving the Novo Nordisk Scientific Exchange website.

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.

ACCESS DENIED

Our Privacy Policy applies only to this and other websites maintained by Novo Nordisk. Links are provided as a public service and for informational purposes only. No endorsement is made or implied. Click "Continue" to leave this site.